Results 61 to 70 of about 5,263,232 (399)

Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer

Frontiers in Oncology, 2021
BackgroundBladder cancer is the 10th most common cancer and most common urothelial malignancy worldwide. Prognostic biomarkers for bladder cancer patients are required for individualized treatment. Monocarboxylate transporter 4 (MCT4), encoded by SLC16A3
Yang Zhao, Bin Zhao, Wei-Hua Yan, Yan Xia, Zhi-Hui Wang, Guo-Yang Zheng, Wen-Da Wang, Yu-Shi Zhang   +7 more
doaj   +1 more source

Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial [PDF]

, 2019
Clinical behavior of non-muscle-invasive bladder cancer (NMIBC) is largely unpredictable, and even patients treated according to European Association of Urology recommendations have a heterogeneous prognosis.
Busetto, Gian Maria, Cortesi, Enrico, de Berardinis, Ettore, Del Giudice, Francesco, Gazzaniga, Paola, Gradilone, Angela, Loreni, Flavia, Nicolazzo, Chiara, Raimondi, Cristina, Sperduti, Isabella   +9 more
core   +1 more source

Bladder Cancer, Version 3.2024.

The Journal of the National Comprehensive Cancer Network
Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic
Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, M. Buyyounouski, Kevin Chan, Sam S Chang, Paul Chang, Terence Friedlander, Richard E Greenberg, K. Guru, H. Herr, Jean Hoffman-Censits, H. Kaimakliotis, Amar U Kishan, Shilajit Kundu, S. Lele, R. Mamtani, Omar Y Mian, Jeff Michalski, Jeffrey S. Montgomery, Mamta Parikh, Anthony L. Patterson, Charles Peyton, E. Plimack, M. Preston, Kyle Richards, W. Sexton, A. Siefker-Radtke, Tyler Stewart, Debasish Sundi, M. Tollefson, J. Tward, Jonathan L Wright, Carly J Cassara, Lisa A. Gurski   +36 more
semanticscholar   +1 more source

Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets

Cancer Research, 2004
Accurate normalization is an absolute prerequisite for correct measurement of gene expression. For quantitative real-time reverse transcription-PCR (RT-PCR), the most commonly used normalization strategy involves standardization to a single ...
C. Andersen, J. L. Jensen, T. Ørntoft
semanticscholar   +1 more source

Urease-powered nanobots for radionuclide bladder cancer therapy

Nature Nanotechnology
Bladder cancer treatment suffers from low therapeutic efficacy. Here the authors present radioactive ^131I-labelled urease-powered nanobots that exhibit enhanced accumulation at the tumour site, enabling effective radionuclide therapy at low doses as an ...
Cristina Simó, Meritxell Serra-Casablancas, Ana C. Hortelão, Valerio Di Carlo, Sandra Guallar-Garrido, S. Plaza-García, Rosa Maria Rabanal, P. Ramos-Cabrer, Balbino Yagüe, Laura Aguado, Lídia Bardia, Sébastien Tosi, Vanessa Gómez-Vallejo, Abraham Martín, Tania Patiño, Esther Julián, Julien Colombelli, Jordi Llop, Samuel Sánchez   +18 more
semanticscholar   +1 more source

Assessment of Luminal and Basal Phenotypes in Bladder Cancer

Scientific Reports, 2020
Genomic profiling studies have demonstrated that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to frontline chemotherapy.
C. Guo, J. Bondaruk, Hui Yao, Ziqiao Wang, Li Zhang, Sangkyou Lee, J. Lee, D. Cogdell, Miao Zhang, Guoliang Yang, V. Dadhania, W. Choi, P. Wei, Jianjun Gao, D. Theodorescu, C. Logothetis, C. Dinney, M. Kimmel, J. Weinstein, D. McConkey, B. Czerniak   +20 more
semanticscholar   +1 more source

The Value of Negative Urinary Dipstick Tests for Haematuria in Patients Undergoing Surveillance for Low-grade Ta Urothelial Cancer: A Two-stage Prospective Clinical Study in 524 Patients

European Urology Open Science
Background and objective: The risk of first recurrence beyond 5 yr for patients with low-grade (LG) Ta non–muscle-invasive bladder cancer (NMIBC) is low enough to consider discontinuing cystoscopic surveillance at that point.
Chandrarajan Premal Shah, Tanya Lord-McKenzie, Antonios Makris, Matthew Trail, Jennifer Gray, Gordon Smith, Paramananthan Mariappan   +6 more
doaj   +1 more source

The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer

Cell Death and Disease, 2021
Bladder cancer is one of the most lethal cancers in the world. Despite the continuous development of medical technologies and therapeutic strategies, the overall survival rate of bladder cancer has not changed significantly.
Lu Yi, Haohui Wang, Wei Li, Kun Ye, Wei Xiong, Haixin Yu, Xin Jin   +6 more
doaj   +1 more source

E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies

Frontiers in Immunology, 2023
With the rapidly increasing incidence of bladder cancer in China and worldwide, great efforts have been made to understand the detailed mechanism of bladder cancer tumorigenesis.
Maoyu Wang, Zhensheng Zhang, Zhizhou Li, Yasheng Zhu, Yasheng Zhu, Chuanliang Xu   +5 more
doaj   +1 more source

RETRACTED: Role of miR‐490‐3p in blocking bladder cancer growth through targeting the RNA‐binding protein PCBP2

Kaohsiung Journal of Medical Sciences, 2022
MiR‐490‐3p is regarded as a tumor suppressor in many cancers, but whether miR‐490‐3p is involved in the development of bladder cancer remains unknown. BALB/c nude mice (male, 15–20 g) were used to investigate the role of MiR‐490‐3p in bladder cancer. The
Cun‐Ming Zhang, Li‐De Song, Jun‐Wei Wang, Hai‐Bo Ye, Song Chen   +4 more
doaj   +1 more source